Gilead Sciences, Inc. announced this week that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® —in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents.
The addition of the adolescent indication is based on a study in HIV-negative individuals 15 to 17 years of age. In the United States, adolescents and young adults 13 to 24 years of age comprised 21 percent of all new infections in 2016, according to the U.S. Centers for Disease Control and Prevention, and 81 percent of those infections were among young men who have sex with men.
Truvada for PrEP is now indicated in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents. Individuals must have a negative HIV test immediately prior to initiating Truvada for PrEP.
READ MORE HERE:
